Trial document



drksid header

  DRKS00018929

Trial Description

start of 1:1-Block title

Title

Investigation of efficacy of different spinal cord stimulation paradigms for the treatment of chronic neuropathic pain

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

PARS

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

Spinal cord stimulation is a treatment option for patients suffering from severe, chronic pain. This type of pain may arise after repeated spine surgery, certain viral infections or in the context of inflammatory diseases of the joints. With spinal cord stimulation, the different pain causes are not treated, but the pain is superimposed by a kind of interference current and thereby reduced. The interference current can be used in different stimulation variants, meaning that it can be applied in different frequencies or in different intensities.

This trial recruits patients implanted with a so-called wireless spinal cord stimulator. There is no standard specifying which variant of stimulation current (intensity and frequency) is most suitable for the treatment of neuropathic pain. Usually, the treating physician determines the type of stimulation current and decides for one of the three common stimulation variants, called "burst", "1kHz" and "1.499kHz”, taking into account the current medical knowledge and the physician’s personal experience. Currently it is not known which of these different stimulation variants is most effective. The purpose of this study is to compare the efficacy of the three most common modes of stimulation.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

Spinal cord stimulation (SCS) is an effective method to treat neuropathic pain. An electric current is applied over an electrode placed on the outer layer of the spinal cord. This current interferes with neuronal activity and can lead to pain relieve in patients suffering from neuropathic pain. A pacemaker is typically implanted subcutaneously and can be operated by the patient via remote control.
SCS devices have been implanted for five decades, however, it is largely unknown which of the many available types of electric currents (so-called SCS paradigms) is most effective. This is mainly due to the fact that, in practice, it is extremely challenging to compare all the different stimulation modalities in an individual patient. Specifically, electrodes leading out though the skin would have to be consecutively connected to different, incompatible SCS devices and be tested over a time period of several weeks. Wound infection risks of such a study would be unacceptably high and blinding of the trial difficult.
This study proposal seizes the capacity of a new type of wireless SCS stimulation device (Stimwave®), which has been approved for SCS and is routinely implanted at the department of neurosurgery at Heidelberg University Hospital. This device enables a blinded and systematic intra-patient comparison of different SCS modalities over extended time periods and without increasing wound infection rates.
The PARS trial is a double-blinded, randomized and controlled study. It aims to compare the clinical effectiveness of the three most relevant SCS paradigms in individual patients. The trial will recruit 60 patients suffering from intractable neuropathic pain, who have been considered for SCS therapy and, prior to the study, were already implanted with a wireless SCS device (Stimwave®). Over a time period of 35 days, patients will be treated consecutively with three different SCS paradigms („burst“, „1kHz“ and „1.499kHz“) as well as placebo stimulation. The primary endpoint of the study is the level of pain measured on the visual analogue scale.
Secondary, exploratory endpoints will be neuropathic pain quality, anxiety, disability and quality of life.

end of 1:1-Block scientific synopsis
start of 1:1-Block forwarded Data

Do you plan to share individual participant data with other researchers?

No

end of 1:1-Block forwarded Data
start of 1:1-Block forwarded Data Content

Description IPD sharing plan:

[---]*

end of 1:1-Block forwarded Data Content
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00018929
  •   2020/01/14
  •   [---]*
  •   yes
  •   Approved
  •   S-738/2019, Ethik-Kommission I der Medizinischen Fakultät Heidelberg
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  • [---]*
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   M54.4 -  Lumbago with sciatica
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   SCS device with SCS paradigm "burst"
  •   SCS device with SCS paradigm 1 kHz
  •   SCS device with SCS paradigm 1.499 kHz
  •   SCS device with SCS paradigm placebo-stimulation
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Interventional
  •   [---]*
  •   Randomized controlled trial
  •   Blinded
  •   patient/subject, investigator/therapist, caregiver, assessor, data analyst
  •   Other
  •   Treatment
  •   Crossover
  •   N/A
  •   N/A
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Self-assessment of pain perception measured on the Visual Analogue Scale (VAS)

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

Self-assessment of pain quality (as determined by Pain Detect Questionnaire), quality of life (as determined by Quality of Life EQ-5D-5L Questionnaire), anxiety perception (as determined by the Hospital Anxiety and Depression Scale) and physical restriction (as determined by the Oswestry Disability Index)

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • University Medical Center 
  • University Medical Center 
  • Medical Center 
  • Medical Center 
  • University Medical Center 
  • Medical Center 
  • University Medical Center 
  • University Medical Center 
  • University Medical Center 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Actual
  •   2020/04/01
  •   60
  •   Multicenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

• Patients suffering from intractable neuropathic pain, who have been considered for SCS therapy according to current German treatment guidelines and, within 48 of study enrolment, were already implanted with a wireless SCS device (Stimwave®)
• Placement of the distal tip of the electrode between upper level of Th8 and lower level of Th12
• leg pain > back pain
• age of patient ≥ 18 Jahre
• Written consent
• Duration of pain history >6 months and < 5 years

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

• Covering of the pain area with the SCS stimulation device (Stimwave®) <90%
• Ischemic pain (i.e. Peripheral artery disease, angioma)
• Chronic primary pain
• Implantation of several SCS electrodes
• Coagulopathy
• Any planned changes in existing pain medication for the duration of trial participation (period of 35 days)
• Pregnancy
• Neurodegenerative disease
• Lack of understanding of the trial and the individual consequences of participating in the trial
• Expected lack of compliance (i.e. patient is not able to complete the trial questionnaires)

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Universitätsklinikum Heidelberg
    • Im Neuenheimer Feld 672
    • 69120  Heidelberg
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Neurochirurgische UniversitätsklinikUniversitätsklinikum Heidelberg
    • Ms.  PD Dr. med.  Rezvan  Ahmadi 
    • Im Neuenheimer Feld 400
    • 69120  Heidelberg
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Neurochirurgische UniversitätsklinikUniversitätsklinikum Heidelberg
    • Ms.  PD Dr. med.  Rezvan  Ahmadi 
    • Im Neuenheimer Feld 400
    • 69120  Heidelberg
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Stimwave LLC
    • 1310 Park Central Blvd S
    • 33064-2217  FL, Pompano Beach
    • United States
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting ongoing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.